Introduction
In the last seven years, genome-wide association studies (GWAS) have been used extensively to identify common genetic variants associated with human diseases and quantitative traits. While there are many replicated and mature, known relationships between genomic regions and phenotypes, very few individual genetic variants have been identified as the risk variant for downstream molecular studies or personalized medicine applications. The lack of true functional variants revealed by GWAS stems from the fact that GWAS is based on linkage disequilibrium (LD), the non-random association of alleles at different variants along the chromosome. That is, GWAS fixed-content products mostly assay presumably neutral common genetic variants that are in LD or "tag" other genetic variants not directly assayed resulting in GWASidentified regions that probably contain the true risk (unassayed) variant.
To identify the true risk variant, a major proposed activity in the "post-GWAS" era is fine mapping. In a fine-mapping experiment, the GWAS-identified region is densely interrogated via thousands of common and rare variants. Fine-mapping experiments can also take advantage of the known LD differences observed across populations. For example, populations of African-descent have lower levels of LD compared with populations of European-descent and therefore may be useful in identifying the risk variant masked by higher levels of LD in other populations. Fine mapping across populations is also useful for identifying population-specific variants associated with phenotypes.
In recognition for the need to fine-map mature GWAS-identified regions originally identified in European-descent populations, the National Human Genome Research Instituted established the Population Architecture using Genomics and Epidemiology (PAGE) study to genotype African American and Asian populations linked to phenotypes using the Illumina Metabochip, a custom iSelect BeadChip designed to fine-map GWAS-identified regions for metabolic diseases and traits. We as Epidemiologic Architecture for Genes Linked to Environment (EAGLE) are genotyping ~15,000 DNA samples linked to de-identified electronic medical records in the Vanderbilt University biorespository (BioVU) for fine mapping within the PAGE study. As the first step in quality control, EAGLE has genotyped 360 HapMap samples from European, African, Asians, and Mexican-descent populations. This short report describes the quality control, variant properties, and the potential for fine mapping of GWAS-identified regions in the anticipated populations within EAGLE and the PAGE study. . Illumina software GenomeStudio (v1.7.4) was used to determine the genotype calls for each variant for each sample, and manual reclustering was performed on all mitochondrial and Y chromosome variants. Data were stored and accessed by the Vanderbilt Computational Genomics Core for quality control and downstream analyses using BC Platforms (Espoo, Finland).
Methods

Study populations
Statistical methods
Standard quality control metrics were generated using PLINKv1.07 4 and PLATOv0.84 5 . F ST calculations were based on the Weir and Cockerham algorithm 6 implemented in PLATO. Allele frequencies and F ST were calculated for CEU, YRI, JPN and CHB combined (ASN), and MEX unrelated samples separately. Linkage disequilibrium (r 2 ) was calculated using independent samples stratified by race/ethnicity using Haploviewv4.2 7 .
Results
We On the x-axis, genetic variant frequencies were binned as monomorphic, rare (0.1%-1-%), less common (1-2.5%), and common (2.5-5%, 5-10%, and 10-50%) by population. Number of observations for each bin is given on the y-axis.
To examine potential population differences for genetic variants targeted by the Metabochip, we first determined minor allele frequencies for every variant by HapMap population. As shown in Figure 1 , the majority of variants for this custom BeadChip are polymorphic. More than one half (58% for ASN) to up to threequarters (75% for YRI) of the alleles assayed by the Metabochip occurred at greater than 1% frequency. Conversely, one quarter (24% for YRI) to more than one-third (38% for ASN) of the variants were monomorphic in this small sample set.
We also calculated a fixation index, F ST, for all pair-wise population comparisons. F ST is an estimate of population differentiation ranging from 0 (no measureable genetic differentiation) to 1.0 (very great genetic differentiation), and its distribution for Metabochip-targeted variants in HapMap samples is given in Figure 2 . The majority (76%) of F ST values are less than 0.15 for all genetic variant pair-wise population comparisons. The most population differentiation was observed between YRI and ASN. Conversely, the least population differentiation was observed between CEU and MEX. We mapped the most highly differentiated SNPs (F ST > 0.15) to dbSNP identifiers (143,750 successfully mapped to known SNPs), and examined the degree to which alleles altered the expression or function of genes using annotation resources from the Genome-Wide Annotation Repository (http://gwar.mc.vanderbilt.edu). We defined two categories of SNP annotation for this analysis: predicted changes to protein function via SIFT and PolyPhen2 algorithms 8, 9 , and prior associations to expression levels of nearby genes 10, 11 . The total number of SNP and gene annotations is shown in tables 2 and 3. Table 4 .
Notably, the most significantly enriched pathways between CEU and MEX indicate a dramatic difference in the functional properties of glutathione and drug metabolism through cytochrome P450. Enrichment of these three pathways is the result of a single SNP -rs1010167 --altering expression of three genes, GSTM1(p=3.88e-7), GSTM2(p=1.54e-7), and GSTM4(p=8.44e-7) 11 . This SNP falls within a region of chromatin that has been functionally categorized as an active promoter by the analysis of Ernst et al. in multiple cell types 12 , and is confirmed to bind multiple proteins via ChIP-seq data as reported by the HaploREG database 13 . Remaining pathways showing high differentiation in the CEU/ASN and CEU/MEX comparisons are largely immune-related, and are driven mostly by functional changes to the Major Histocompatibility Complex (MHC) found on chromosome 6. Interestingly, there were no significant pathways found for differentiated functional SNPs involving YRI comparisons. To illustrate the fine-mapping potential of densely targeted regions on the Metabochip, we calculated linkage disequilibrium (r2) by HapMap population for the CELSR2/PSRC1/SORT1 locus known to be associated with low-density lipoprotein cholesterol levels from GWA studies in European-descent populations [14] [15] [16] . Consistent with the observations of Buyske et al 17 in samples from African American and Swedish participants, we observed less LD in YRI compared with CEU for this genomic region. To extend the observations made by Buyske et al, we examined LD for the same genomic region in HapMap samples of Asian and Mexican ancestry (Figure 3 c,d ). As observed with minor allele frequency and FST, the CEU and MEX populations displayed similar levels of LD for this genomic region. In contrast, the ASN population had LD patterns that were distinct from CEU, YRI, and MEX LD patterns. For the ASN population, the CELSR2/PSRC1/SORT1 locus contained strong pair-wise LD statistics punctuated by weak LD.
Conclusions
We demonstrate here that the Metabochip custom BeadChip produces high-quality data for diverse populations from the International HapMap Project. We further show that the majority of variants observed in all populations considered were common and that a sizeable fraction of variants were monomorphic. Finally, we demonstrate population differences in both allelic diversity and LD patterns, both of which will impact the effectiveness of fine-mapping efforts that employ this BeadChip in the post-GWAS era.
Many of the observations reported here were expected based on population genetics theory and recent empirical genome-wide data from the International HapMap Project 18, 19 and 1000 Genomes Project
20
. That is, as expected, the greatest population differentiation (as measured by F ST ) was observed between Africandescent and Asian-descent populations 21 . However, other observations such as the proportion of common and rare variants did not follow expectations given the bias in genetic variant selection for this custom BeadChip 22 . From our FST analysis, we also observe significant differentiation of functional alleles within drug metabolism and auto-immune associated pathways between CEU and ASN/MEX populations. These variants may explain some aspects of ethnic differences in HLA-based autoimmune disease susceptibility, and indicates that cytochrome P450 drug metabolism may be altered in individuals of Mexican ancestry.
A major limitation of this study is sample size. With only 60 to 90 independent samples per HapMap population, our ability to observe rare alleles targeted by the Metabochip was limited for any HapMap population. Indeed, although the shape of the allelic distribution was similar, proportionally more variants in our dataset were classified as common or monomorphic compared with Buyske et al reflecting our limited ability to observe rare variants. Larger sample sizes will be required to take advantage of the full range of the allelic spectrum targeted by the Metabochip for fine mapping.
A final observation made here that will impact fine-mapping efforts is the extent of LD for an LDL-C associated region across populations. As Buyske et al 2 noted, the breakdown of LD in African Americans for this region (and West Africans here) will be useful in identifying the true risk variant in a region with high LD in European populations. However, we note in ASN that the same genomic region has very high LD and thus this custom BeadChip may not fine map equally well for all targeted GWAS-identified regions for all populations. Because this custom BeadChip was designed using early iterations of the 1000 Genomes Project data, additional iterations of chips designed for fine mapping will be required to capture the latest genetic diversity data now emerging in non-European descent populations from later releases of the 1000 Genomes Project.
